These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 9311977)
1. Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution. Papageorgiou AC; Shapiro R; Acharya KR EMBO J; 1997 Sep; 16(17):5162-77. PubMed ID: 9311977 [TBL] [Abstract][Full Text] [Related]
2. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot". Shapiro R; Ruiz-Gutierrez M; Chen CZ J Mol Biol; 2000 Sep; 302(2):497-519. PubMed ID: 10970748 [TBL] [Abstract][Full Text] [Related]
3. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A. Chen CZ; Shapiro R Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. Johnson RJ; McCoy JG; Bingman CA; Phillips GN; Raines RT J Mol Biol; 2007 Apr; 368(2):434-49. PubMed ID: 17350650 [TBL] [Abstract][Full Text] [Related]
5. Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A. Chen CZ; Shapiro R Biochemistry; 1999 Jul; 38(29):9273-85. PubMed ID: 10413501 [TBL] [Abstract][Full Text] [Related]
6. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. Leonidas DD; Shapiro R; Allen SC; Subbarao GV; Veluraja K; Acharya KR J Mol Biol; 1999 Jan; 285(3):1209-33. PubMed ID: 9918722 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A. Kobe B; Deisenhofer J J Mol Biol; 1996 Dec; 264(5):1028-43. PubMed ID: 9000628 [TBL] [Abstract][Full Text] [Related]
9. Unexpected binding mode for 2'-phosphoadenosine-based nucleotide inhibitors in complex with human angiogenin revealed by heteronuclear NMR spectroscopy. Tonan K; Xu P; Jenkins JL; Russo A; Shapiro R; Ni F Biochemistry; 2003 Sep; 42(38):11137-49. PubMed ID: 14503864 [TBL] [Abstract][Full Text] [Related]
10. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Newton DL; Xue Y; Olson KA; Fett JW; Rybak SM Biochemistry; 1996 Jan; 35(2):545-53. PubMed ID: 8555226 [TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the complex of human RNase inhibitor and human eosinophil-derived neurotoxin (RNase 2). Teufel DP; Kao RY; Acharya KR; Shapiro R Biochemistry; 2003 Feb; 42(6):1451-9. PubMed ID: 12578357 [TBL] [Abstract][Full Text] [Related]
12. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481 [TBL] [Abstract][Full Text] [Related]
13. High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors. Leonidas DD; Chavali GB; Oikonomakos NG; Chrysina ED; Kosmopoulou MN; Vlassi M; Frankling C; Acharya KR Protein Sci; 2003 Nov; 12(11):2559-74. PubMed ID: 14573867 [TBL] [Abstract][Full Text] [Related]
14. Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor. Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR Biochemistry; 1999 Aug; 38(32):10287-97. PubMed ID: 10441122 [TBL] [Abstract][Full Text] [Related]
15. Crystal structure of bovine angiogenin at 1.5-A resolution. Acharya KR; Shapiro R; Riordan JF; Vallee BL Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2949-53. PubMed ID: 7708754 [TBL] [Abstract][Full Text] [Related]
16. Crystal structures of ribonuclease A complexes with 5'-diphosphoadenosine 3'-phosphate and 5'-diphosphoadenosine 2'-phosphate at 1.7 A resolution. Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR Biochemistry; 1997 May; 36(18):5578-88. PubMed ID: 9154942 [TBL] [Abstract][Full Text] [Related]
17. Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38-41. Holloway DE; Chavali GB; Hares MC; Baker MD; Subbarao GV; Shapiro R; Acharya KR Biochemistry; 2004 Feb; 43(5):1230-41. PubMed ID: 14756559 [TBL] [Abstract][Full Text] [Related]
18. Ribonuclease inhibitor regulates neovascularization by human angiogenin. Dickson KA; Kang DK; Kwon YS; Kim JC; Leland PA; Kim BM; Chang SI; Raines RT Biochemistry; 2009 May; 48(18):3804-6. PubMed ID: 19354288 [TBL] [Abstract][Full Text] [Related]
19. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Shapiro R; Vallee BL Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2238-41. PubMed ID: 3470787 [TBL] [Abstract][Full Text] [Related]
20. Interaction of human placental ribonuclease with placental ribonuclease inhibitor. Shapiro R; Vallee BL Biochemistry; 1991 Feb; 30(8):2246-55. PubMed ID: 1998683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]